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Fragile X syndrome is caused by an expansion of a polymorphic CGG triplet repeat that results in silencing of
FMR1 expression. This expansion triggers methylation of FMR1’s CpG island, hypoacetylation of associated
histones, and chromatin condensation, all characteristics of a transcriptionally inactive gene. Here, we show that
there is a graded spectrum of histone H4 acetylation that is proportional to CGG repeat length and that correlates
with responsiveness of the gene to DNA demethylation but not with chromatin condensation. We also identify
alterations in patient cells of two recently identified histone H3 modifications: methylation of histone H3 at lysine
4 and methylation of histone H3 at lysine 9, which are marks for euchromatin and heterochromatin, respectively.
In fragile X cells, there is a decrease in methylation of histone H3 at lysine 4 with a large increase in methylation
at lysine 9, a change that is consistent with the model of FMR1’s switch from euchromatin to heterochromatin in
the disease state. The high level of histone H3 methylation at lysine 9 may account for the failure of H3 to be
acetylated after treatment of fragile X cells with inhibitors of histone deacetylases, a treatment that fully restores
acetylation to histone H4. Using 5-aza-2′-deoxycytidine, we show that DNA methylation is tightly coupled to the
histone modifications associated with euchromatin but not to the heterochromatic mark of methylation of histone
H3 at lysine 9, consistent with recent findings that this histone modification may direct DNA methylation. Despite
the drug-induced accumulation of mRNA in patient cells to 35% of the wild-type level, FMR1 protein remained
undetectable. The identification of intermediates in the heterochromatinization of FMR1 has enabled us to begin
to dissect the epigenetics of silencing of a disease-related gene in its natural chromosomal context.
Introduction
Fragile X mental retardation is caused by mutation of
the FMR1 gene (MIM 309550) located at Xq27.3. Of
the cases of fragile X, 195% are due to the expansion
of a CGG triplet repeat tract located at the 5′ end of
FMR1 (Warren and Sherman 2001). In the general pop-
ulation, there is a range of 6–54 repeats in this tract,
with a mode of 30 (Fu et al. 1991; Snow et al. 1993).
In patients with fragile X, the CGG repeat tract expands
to 1200 CGG repeats and can be as large as 1,000 re-
peats (Kremer et al. 1991; Verkerk et al. 1991). This
expansion triggers methylation of cytosines in the CpGs
in the repeat tract and in the flanking sequence, including
the FMR1 gene promoter, resulting in the silencing of
FMR1 transcription (Pieretti et al. 1991; Sutcliffe et al.
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1992; Hornstra et al. 1993). Treatment of fragile X cells
with the DNA methylation inhibitor 5-aza-2′-deoxy-
cytidine (azadC) results in the loss of methylation at ex-
panded FMR1 DNA and reactivates transcription of the
gene (Chiurazzi et al. 1998, 1999; Coffee et al. 1999).
This result suggests that DNA methylation, not the ex-
pansion itself, is the major factor in the loss of tran-
scriptional activity of FMR1 in patients with fragile X.
DNA methylation has long been associated with the
transcriptional repression of many genes (Eden and Ce-
dar 1994; Li 1999). The effect of DNA methylation on
gene silencing can be direct, by inhibition of transcrip-
tion factor binding, or indirect, through the induction
of changes in local chromatin structure at the site of
methylation. One model suggests that DNA methyla-
tion induces changes in chromatin architecture through
the recruitment of histone deacetylases (HDACs) by a
methyl CpG binding (MBD) protein such as MeCP2
(Jones et al. 1998; Nan et al. 1998). Histone deacetyl-
ation is thought to result in a tighter association between
the histone amino termini and DNA, resulting in a con-
densed chromatin structure that excludes critical tran-
scription factors. In addition, it has been suggested that
removal of the acetyl groups from the histones facilitates
924 Am. J. Hum. Genet. 71:923–932, 2002
nucleosome-nucleosome contacts, thus allowing stack-
ing of the nucleosomes and formation of higher-order
structures (Bestor 1998).
In addition to lysine acetylation, other modifications
of histones, such as methylation of lysine and arginine,
ubiquitination, and phosphorylation, have been iden-
tified (Strahl and Allis 2000; Jenuwin and Allis 2001).
In addition to a direct influence on the structure of chro-
matin, these modifications may also serve as “marks”
for interactions with other chromatin proteins (Strahl
and Allis 2000; Jenuwin and Allis 2001). For example,
the transcription factors PCAF and TAFII250 selectively
interact with acetylated histone tails through their
bromodomains (Dhalliun et al. 1999; Jacobson et al.
2000). Likewise, proteins containing chromodomains,
such as HP1, interact with histone H3 tails methyl-
ated at lysine 9, a mark associated with heterochro-
matin (Bannister et al. 2001; Lachner et al. 2001).
HP1 has been shown to dimerize in solution, leaving
the chromodomains at the ends of flexible linkers,
free for association with histone H3 methylated at ly-
sine 9, providing an attractive model for how higher-
order chromatin structure can be organized in regions
marked by histone H3 methylation at lysine 9 (Brasher
et al. 2000; Jenuwin and Allis 2001). Interestingly, a
recent report shows that disruption of methylation of
histone H3 at lysine 9 perturbs DNA methylation in
Neurospora crassa, indicating that histone methylation
can direct DNA methylation (Tamaru and Selker 2001).
Methylation of histone H3 at lysine 4, on the other
hand, is a conserved euchromatic mark that is associ-
ated with transcriptionally active genes but not with
inactive facultative heterochromatin (Strahl et al. 1999;
Litt et al. 2001; Boggs et al. 2002; Peters et al. 2002).
Observations such as these have led to the “histone
code” hypothesis, according to which a specific con-
stellation of modified histone residues are thought to
regulate unique biological outcomes through specific in-
teractions with other components of chromatin (Strahl
and Allis 2000; Jenuwin and Allis 2001).
Elsewhere, we demonstrated that there is a loss of
acetylation of histone H3 and H4 at FMR1 in fragile
X cells compared with normal cells (Coffee et al. 1999).
Here, we demonstrate that naturally occurring fragile
X alleles, which carry various numbers of CGG repeats,
possess a level of H4 acetylation that is inversely pro-
portional to their CGG repeat tract length and to the
cells’ delayed responsiveness to azadC treatment. How-
ever, increased acetylation of histone H4 associated with
these FMR1 alleles, either naturally occurring or in-
duced by the HDAC inhibitor trichostatin A (TSA), was
not sufficient to relax the condensed chromatin struc-
ture at the locus. We also identify fragile X–specific
alterations in two additional histone modifications at
FMR1: methylation of histone H3 at lysine 4 (a mark
for euchromatin) and methylation of lysine 9 (a mark
for heterochromatin). Histone H3 at FMR1 in fragile
X cells is methylated at lysine 9 and undermethylated
at lysine 4. The modification is similar to the code that
is found in heterochromatic regions of the genomes of
model organisms and to the code that is imprinted both
on human genes and on the inactive X chromosome in
all mammals (Strahl et al. 1999; Litt et al. 2001; Xin
et al. 2001; Boggs et al. 2002; Peters et al. 2002). Treat-
ment of fragile X cells with HDAC inhibitors has little,
if any, effect on these modifications, suggesting that his-
tone H3 methylation at lysine 9 blocks the acetylation
of this residue. Finally, we show that FMR1 DNA meth-
ylation, altered by treatment with azadC, is tightly cou-
pled to changes in histone H3 and H4 acetylation, and
to methylation of histone H3 at lysine 4, all marks for
euchromatin. However, methylation of histone H3 at
lysine 9, a mark for heterochromatin, did not follow
drug-induced changes in DNA methylation, indicating
that it may operate independently of DNA methylation.
Material and Methods
Cell Lines, Cell Culture, and Drug Treatment
Epstein-Barr virus (EBV)–transformed lymphoblas-
toid cell lines E3 and E4 derived from male patients with
fragile X and carrying FMR1 alleles of 230 CGG repeats
or 410 CGG repeats (data not shown), respectively, were
a generous gift from G. Neri (Universita Cattolica,
Rome) (Chiurazzi et al. 1999). The EBV-transformed
lymphoblastoid cell line J-1, carrying an unmethylated
30–CGG repeat allele, was derived from an unaffected
male and GM3200A (available from Coriell Cell Re-
positories), carrying a methylated 530–CGG repeat al-
lele, was derived from a male patient with fragile X. The
cells were cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal bo-
vine serum and 100 U/ml penicillin and 100mg/ml
streptomycin.
TSA (330 nM; Sigma) or sodium butyrate (10 mM;
Sigma) was added to the media for 24 h; azadC (1 mM;
Sigma) was added to the media and was replenished
every 48 h by replacement of half the conditioned media
with fresh media and drug. In the azadC withdrawal
experiment, cells were synchronized with two 8-h blocks
of thymidine prior to addition of azadC (Chiurazzi et
al. 1998).
Chromatin Immunoprecipitation
We performed chromatin immunoprecipitation as de-
scribed elsewhere (Coffee et al. 1999). The chromatin
solution was used for immunoprecipitation with anti-
bodies directed against histone H4 acetylated at lysines
5, 8, 12, and 16 (Upstate Biotech), histone H3 acetylated
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Figure 1 Fragile X cell lines treated with azadC. A, Light cycler
RT-PCR quantitation of FMR1 transcript following azadC treatment
of fragile X cell lines harboring 230 CGGs, 410 CGGs, or 530 CGGs.
The amount of FMR1 transcript in 100 ng of total RNA (expressed
as percent of transcript from a normal cell line) is plotted against the
time of azadC treatment. B, RT-PCR and western blot analysis of
azadC-treated normal control cells and fragile X cells with either 230
CGGs or 530 CGGs. Cells were treated with azadC for the indicated
times, and samples were collected for conventional RT-PCR and west-
ern blot analysis. In the western analysis, the indicated amounts of
total cell lysate were loaded on the gel. A cross-reacting band of un-
known identity is observed when large amounts of protein (60 mg)
from all cell lines, regardless of treatment, are loaded in a lane.
at lysines 9 and 14 (Upstate Biotech), histone H3 di-
methylated at lysine 9 (Upstate Biotech), and histone H3
dimethylated at lysine 4 (Upstate Biotech). Prior to PCR
analysis, the IP-DNAs were digested with XhoI to sep-
arate the CGG repeat tract, which interferes with am-
plification. The PCR conditions and primers used were
as described elsewhere (Coffee et al. 1999). The PCR
products were electrophoresed, and the image was cap-
tured using the Eagle Eye imaging system and was an-
alyzed with Molecular Dynamics ImageQuant software.
RT-PCR and LightCycler RT-PCR
Total RNA was isolated using Trizol (Gibco BRL) or
RNeasy (Qiagen), according to the manufacturers’ in-
structions. Conventional RT-PCR was performed using
the GeneAmp RNA PCR kit (Perkin Elmer), as described
elsewhere (Coffee et al. 1999). LightCycler RT-PCR was
performed using the LightCycler RNA amplification kit
(Roche), according to the manufacturers’ suggested con-
ditions for one-step RT-PCR. Total RNA (100 ng) was
used for each sample. The PCR conditions were as
follows: RT at 55C for 10 min, followed by an initial
denaturation at 95C for 30 s, then 45 cycles of 95C
for 1 s, 60C for 10 s, and 72C for 30 s. SYBR Green
I (Roche) was used as the fluorescent marker to monitor
DNA accumulation. The primers used were 5′-GATGA-
AGATACCTGCACATTC-3′ and 5′-TAGCTCCAATC-
TGTCGCAACTGC-3′, yielding a 593-bp product. Melt-
ing-curve analysis of the reactions was done using the
LightCycler software (Roche).
Western Blot Analysis
Protein was isolated and quantified using the Bradford
reagent (BioRad) and amounts specified in figure 1 were
loaded onto a 7.5% SDS polyacrylamide gel. The re-
solved protein was transferred to Hybond-P membrane
(Amersham), was stained with PonceauS (Sigma) to con-
firm transfer, and was then blocked in 10% milk (Car-
nation) in PBS/0.2% Tween-20 for 1 h. The membrane
was probed with the anti-FMR1 protein (FMRP) mon-
oclonal antibody 1FM 1AC hybridoma supernatant at
1:10 (Devys et al. 1993) for 3 h, washed, and then
probed with an anti-mouse Ig, Fc-specific-antibody cou-
pled to HRP (Sigma) for 1 h. After four 15-min washes,
the blot was developed using a chemiluminescent sub-
strate (Amersham) and was then exposed to film.
Nuclease Accessibility
Approximately 107 EBV-transformed lymphoblastoid
cells were washed with PBS and permeabilized with
L-a-lysophosphatidylcholine, as described elsewhere
(Eberhart et at. 1996). The cells were collected and sus-
pended in NEB2 restriction enzyme buffer (New Eng-
land Biolabs), and the indicated amounts of MspI were
added. The samples were incubated for 60 min at 37C
and treated with proteinase K, and the DNA was iso-
lated, digested with HindIII, and analyzed by Southern
blot hybridization as described elsewhere (Pieretti et al.
1991).
Southern Blot Analysis
DNA for Southern blot analysis was isolated from the
cells by use of a salting-out procedure (Miller et al.
1988). Genomic DNA (10 mg) was digested with the
restriction enzyme pair of HindIII and BssHII. The prod-
ucts of the digestion were separated by electrophoresis
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on an 0.8% agarose gel and transferred to Hybond N
membrane (Amersham). The membrane was hybridized
with a 32P-labeled 5.2-kb fragment of FMR1 DNA iso-
lated from plasmid pE5.1 (Pieretti et al. 1991).
Results
Histone H4 Acetylation at FMR1 Is Proportional to
CGG Repeat Tract Length and to Responsiveness to
azadC Treatment
Patients with fragile X harbor CGG repeat expansions
that vary from ∼200 repeats to 11,000 repeats. Previous
work suggested that fragile X cell lines carrying shorter
CGG repeat tracts were more responsive to azadC
(Chiurazzi et al. 1999). Using light-cycler RT-PCR, we
carefully measured the amount of FMR1 transcript in-
duced by azadC over time in three different male fragile
X cell lines harboring alleles with ∼230, ∼410, or ∼530
CGG repeats. These alleles are fully methylated at the
diagnostic EagI and BssHII restriction sites located in
the FMR1 promoter (data not shown). FMR1 transcripts
became readily detectable in the 230-CGG repeat cell
line at day 4, with the longer-repeat cell lines taking until
day 6 to produce an equivalent amount of FMR1 tran-
script (fig. 1). FMR1 mRNA continued to accumulate
in all the cell lines throughout this course of treatment,
with the amount of FMR1 transcript present at day 8
being inversely proportional to CGG repeat tract length
(fig. 1).
It has been reported that CGG repeat expansions, of
the size usually found in patients, in the FMR1 transcript
can impair translation by impeding the migration of the
40S subunit along mRNA (Feng et al. 1995). However,
FMRP has been detected after azadC treatment of fragile
X syndrome cells (Chiurazzi et al. 1998). Since we
achieved such high levels of FMR1 transcript during
reactivation of the short allele–containing cells with
azadC, we used western blot analysis to determine
whether FMRP also accumulated. In normal cells,
FMRP could be detected with as little as 3 mg of total
cell protein lysate loaded on the gel (fig. 1B). However,
in fragile X cells, FMRP could not be detected, even
when 20-fold more protein was analyzed. Therefore, in
the 230-CGG repeat cell line in which transcription was
reactivated to a level 135% of normal after 8 d of azadC
treatment, FMRP remained undetectable (!5% of nor-
mal), indicating that FMRP translation is inhibited by
CGG expansion.
The finding of differential reactivation led us to test
the idea that histone acetylation at FMR1 differed as a
function of repeat size. Using chromatin immunoprecip-
itation (ChIP), we found that histone H3 was signifi-
cantly hypoacetylated and was barely detectable in the
three fragile X cell lines (fig. 2). The average ratios of
histone H3 acetylation, relative to the constitutively ex-
pressed, X-linked G6PD gene, for the fragile X cell lines
carrying repeats of 230 CGGs, 410 CGGs, or 530 CGGs
were 0.07, 0.03, and !0.01, respectively, versus 1.14 for
normal cells (fig. 2). The average ratios of histone H4
acetylation at FMR1 were 0.63, 0.23, and 0.13, respec-
tively, versus 1.11 for normal cells. Therefore, there was
a graded loss of histone acetylation, especially histone
H4, that was proportional to CGG repeat length and to
the cell line’s responsiveness to azadC, suggesting that
alleles with longer CGG repeat tracts are further down
a pathway of transcriptional repression.
Acetylation of Histone H4 Alone Does Not Relax the
Condensed Chromatin Structure at Fragile X FMR1
Alleles
Relative to normal cells, chromatin at FMR1 in per-
meabilized fragile X cells is resistant to MspI digestion,
indicating that it is organized into a condensed state
(Eberhart et al. 1996). The availability of cell lines har-
boring FMR1 alleles with a spectrum of histone H4 acet-
ylation led us to test whether the higher levels of histone
H4 acetylation are a reflection of a more open chromatin
structure. Using the MspI nuclease accessibility assay
(Eberhart et al. 1996), we gauged the compaction of
chromatin at FMR1 associated with various levels of
histone H4 acetylation. In permeabilized normal cells,
cleavage at the 16 MspI sites at the FMR1 promoter (fig.
3A) was readily observed at all MspI concentrations (fig.
3B, lanes 1–4). The same sites were much less accessible
to MspI in permeabilized fragile X cells with 530 CGG
repeats, where histone H4 was almost completely de-
acetylated (fig. 3B, lanes 9–12). FMR1 DNA associated
with an increased level of histone H4 acetylation at the
naturally occurring 230-CGG repeat allele, where H4
acetylation was ∼50% of normal, was also highly re-
sistant to MspI digestion (fig. 3B, lanes 5–8). Finally,
TSA treatment of the 530-CGG repeat cell line, which
restores H4 acetylation to normal levels but has little or
no effect on H3 acetylation (Coffee et al. 1999; also see
fig. 4), did not observably increase accessibility of FMR1
DNA to MspI (fig. 3B, lanes 13–16). This indicates that
even a wild-type level of histone H4 acetylation is not
sufficient to open the condensed heterochromatin-like
structure at FMR1 in patients with fragile X, which may
explain, in part, why TSA does not efficiently reactivate
transcription of FMR1 alleles in fragile X cells (Chiurazzi
et al. 1999; Coffee et al. 1999).
Histone H3 Methylation Is Increased at Lysine 9 and Is
Decreased at Lysine 4 at FMR1 in Fragile X Cells
Recently, it has been shown that methylation of his-
tone H3 at lysine 4 or lysine 9 is selectively enriched in
euchromatic and heterochromatic regions of chromo-
somes, respectively (Strahl et al. 1999; Rea et al. 2000;
Boggs et al. 2002; Peters et al. 2002). We used ChIP
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Figure 2 Histone H3 and histone H4 acetylation at FMR1 in
fragile X cell lines harboring 230 CGGs, 410 CGGs, or 530 CGGs.
A, A representative multiplex PCR analysis of DNAs immunoprecip-
itated with either anti-acetyl histone H3 or anti-acetyl histone H4
antibodies from a normal cell line or three fragile X cell lines. The top
band is specific for the constitutively active, X-linked glucose 6-phos-
phate dehydrogenase (G6PD) gene and the bottom band specific for
FMR1. B, Quantitation of the level of histone H3 or H4 acetylation
associated with FMR1 in the normal and the three fragile X cell lines.
Amount of FMR1 DNA immunoprecipitated, relative to the internal
control G6PD DNA, is averaged from three independent experiments.
Error bars p 1 SD.
Figure 3 Nuclease accessibility analysis of FMR1 DNA asso-
ciated with various levels of acetylated histone H4. A, Map of the 5′
end of FMR1, showing the location of the relevant restriction sites,
the transcriptional start site, and the CGG repeat tract. B, Southern
analysis of FMR1 DNA recovered after nuclease accessibility analysis
from a normal cell line (lanes 1–4), the 230-CGG repeat fragile X cell
line (lanes 5–8), the 530-CGG repeat fragile X cell line (lanes 9–12),
and the 530-CGG repeat cell line treated with 330 nM TSA for 24 h
(lanes 13–16).
analysis to determine whether these chromatin marks
were altered at FMR1 in fragile X cells. Histone H3
methylation at lysine 4 was significantly reduced at
FMR1 in fragile X cells (fig. 4, “MeH3-K4,” lanes 1 and
2). Conversely, the amount of methylation of histone H3
at lysine 9 at FMR1 in fragile X cells was significantly
greater than the amount observed at FMR1 in normal
cells (fig. 4, “MeH3-K9,” lanes 1 and 2). As expected,
methylation of histone H3 at lysine 9 was not observed
at the constitutively active G6PD gene. These results
demonstrate a complementary pattern of histone H3
methylation at FMR1 in normal and fragile X cells, in
which the euchromatic marks in normal cells are re-
placed with heterochromatic marks in fragile X cells.
An individual lysine 9 of histone H3 can be acetylated
or methylated but cannot possess both groups simul-
taneously. To determine whether methylation of histone
H3 at FMR1 changed in a coordinated fashion with
acetylation, we used ChIP to assess alterations in these
modifications at FMR1 in fragile X cell lines after treat-
ment with the HDAC inhibitors sodium butyrate or
TSA. After drug treatment, histone H4 acetylation at
FMR1 increased to wild-type levels, as shown previously
(fig. 4, “AcH4”) (Coffee et al. 1999). There was a small
increase in methylation of histone H3 at lysine 4 with
sodium butyrate (fig. 4, “MeH3-K4”). Methylation of
H3 lysine 9 was not reduced, and may slightly increase
after the drug treatment (fig. 4, “AcH3” and “MeH3-
K9”). These data suggest that methylation of histone H3
at lysine 9 blocks its acetylation, preventing the transi-
tion of FMR1 from a heterochromatic-like state to a
euchromatic-like state.
Acetylation of Histone H3 and H4 Is Tightly Coupled
to DNA Methylation
Elsewhere, we and others have demonstrated that
treatment of fragile X cells with azadC resulted in tran-
scriptional reactivation of FMR1 (Chiurazzi et al. 1998,
1999; Coffee et al. 1999). This reactivation is accom-
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Figure 4 ChIP analysis of histone H4 and H3 acetylation, H3
methylation at lysine 9 and histone H3 methylation at lysine 4 in a
normal and a fragile X cell line carrying a 530-CGG repeat allele
without HDAC inhibitor treatment (lanes 1 and 2) and the fragile X
cell line treated with 330 nM TSA or 10 mM sodium butyrate for 24
h (lanes 3 and 4). The antibodies used and the lysine modifications
they are directed against are indicated for each panel.
Figure 5 DNA methylation, ChIP, and RT-PCR analysis of
FMR1 after addition and withdrawal of azadC. The fragile X cell line
harboring 530 CGG repeats was treated with 1 mM azadC for 5 d
(shaded area), followed by removal of the drug from the media. The
treated cells continued to be passaged for an additional 30 d. Histone
H3 and H4 acetylation is plotted as a percentage of untreated normal,
the amount of demethylation is plotted as percent of FMR1 DNAs
cleaved with the methyl-sensitive restriction enzyme BssHII, and the
amount of FMR1 transcript is plotted as the percent of FMR1 tran-
script found in untreated normal cells.
panied by an increase of both histone H3 and H4 acet-
ylation at the 5′ end of the gene (Coffee et al. 1999;
and shaded portion of fig. 5). To determine whether
the changes in DNA methylation and the concomitant
changes in histone acetylation and transcription are sta-
ble without the continual presence of azadC, the drug
was removed from the media, and the cells were pas-
saged for an additional 30 d (unshaded portion of fig.
5). Samples were collected at various intervals and were
assayed for DNA methylation, by digestion with meth-
ylation-sensitive restriction enzymes, histone acetylation,
and FMR1 mRNA levels (fig. 5). Immediately following
withdrawal of azadC, there was an increase in DNA
methylation with a parallel decrease in histone acety-
lation. Steady-state FMR1 mRNA levels began to de-
crease several days later. Twenty days after the removal
of azadC, FMR1 DNA became completely remethylated
at the diagnostic BssHII site in the FMR1 promoter,
histone acetylation returned to pretreatment levels, and
FMR1 transcript became undetectable (fig. 5). Thus, the
changes in DNA methylation and histone acetylation
induced by azadC at FMR1 are not maintained without
the continuous presence of the drug, and the hetero-
chromatic nature of FMR1 in fragile X cells is tightly
coupled to DNA methylation.
Methylation of Histone H3 at Lysine 9 Does Not
Follow Drug-Induced Loss of DNA Methylation and
Transcriptional Reactivation of FMR1
Methylation of histone H3 at lysine 9 and methylation
of cytosines in CpG dinucleotides are features of het-
erochromatin (Jenuwin and Allis 2001). The molecular
link between these two epigenetic changes, however, re-
mains to be defined. To determine whether histone H3
methylation is coupled to DNA methylation at FMR1,
we used the azadC-mediated demethylation of FMR1
DNA as a model to assess the changes in histone H3
methylation that occurs during the switch from a tran-
scriptionally inactive heterochromatin-like state to a
transcriptionally active euchromatin-like state. DNA de-
methylation became detectable (as assessed by cleavage
at the methyl-sensitive BssHII restriction sites located in
the FMR1 promoter) as early as 2 d after addition of
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Figure 6 DNA methylation, RT-PCR, and ChIP analysis of
FMR1 during the course of azadC treatment. The fragile X cell line
carrying 410 CGG repeats was treated with 1 mM azadC for 16 d.
Equal numbers of cells were harvested at the indicated times for DNA,
RNA, and chromatin analysis. DNA demethylation is expressed as the
sum of intensities of the digested bands divided by the sum of the
intensities of the digested and undigested bands. Histone methylation
at lysine 9 during the course of azadC treatment is plotted as percent
of untreated for three independent experiments.
azadC, and it continued to increase until approximately
day 8, when it plateaued at ∼13%–14% (fig. 6). FMR1
transcript became detectable by RT-PCR at approxi-
mately day 6 and increased steadily throughout the re-
mainder of the treatment (fig. 6). Like the euchromatic
marks of histone H3 and H4 acetylation, histone H3
methylation at lysine 4 increases at FMR1 steadily
throughout the treatment, doubling from 45% of the
normal level in the untreated fragile X cell to 90% of
normal after 16 d of azadC treatment (data not shown).
Methylation of histone H3 at lysine 9 decreased initially
at FMR1, dropping to about half the amount seen in
untreated cells after 2 d of treatment, but it reproducibly
recovered and by day 16 was at or above the level seen
in untreated cells (fig. 6). These results demonstrate that
the heterochromatic mark of methylation of histone H3
at lysine 9 at FMR1 did not track with DNA demethy-
lation, as did the euchromatic marks of H3 methylation
at lysine 4 and histone acetylation, suggesting that this
histone modification is related in a more complex way
to DNA methylation.
Discussion
Elsewhere, we showed that treatment of fragile X cells
with TSA resulted in acetylation of histone H4 at FMR1
but had little, if any, effect on histone H3 acetylation
and failed to reactivate transcription (Coffee et al. 1999).
Loss of DNA methylation after azadC treatment resulted
in an increase in both histone H3 and H4 acetylation
and transcriptional reactivation. This suggested that his-
tone H3 deacetylation, but not histone H4 deacetylation,
is linked to DNA methylation and transcriptional si-
lencing (Coffee et al. 1999). Here, we extend this initial
observation by showing that acetylation of histone H4
at naturally occurring fragile X FMR1 alleles can vary
between 10% and 50% of normal levels. The extent of
histone H4 deacetylation correlated with increasing
CGG repeat length. One possible basis for this obser-
vation could be an increasing abundance of HDACs at
the locus, resulting from a larger number of binding sites
for methylcytosine-binding proteins in the longer CGG
repeat alleles. Histone H3 was more profoundly and
uniformly deacetylated across the spectrum of CGG re-
peat sizes, suggesting that loss of this modification is
more important in transcriptional silencing. A similar
linkage of DNA methylation to histone H3 deacetyla-
tion, but not histone H4 deacetylation, was found at the
imprinted Snrpn and U2af1-rs1 genes in mice (Gregory
et al. 2001).
The spectrum of histone H4 acetylation found at
FMR1 in fragile X cells suggested that there is a gra-
dation in the possible heterochromatin-like states that
FMR1 can populate. Supporting this notion is the ob-
servation shown here, and also by others (Chiurazzi et
al. 1999), that FMR1 transcription is reactivated earlier
by azadC treatment in fragile X cells with shorter CGG
repeat expansions. The earlier azadC reactivation of
FMR1 that possesses partially acetylated histones is
reminiscent of the synergistic reactivation achieved by
dual treatment with HDAC inhibitors and a subthresh-
old dose of azadC (Chiurazzi et al. 1999). This relatively
930 Am. J. Hum. Genet. 71:923–932, 2002
large restoration of FMR1 mRNA is not accompanied
by a proportional increase in FMRP accumulation. This
is consistent with prior work indicating that expansion-
containing mRNA is refractory to efficient translation
(Feng et al. 1995).
Partial or even full acetylation of histone H4, how-
ever, did not increase the accessibility of FMR1 chro-
matin to nucleases, indicating that H4 acetylation is not
sufficient to relax chromatin condensation at FMR1.
However, the observation that histone H4 acetyla-
tion—either at the naturally occurring 230–CGG repeat
allele or induced by HDAC inhibitor treatment of cells
with large repeat tracts—augments azadC-mediated
transcriptional reactivation suggests that the extent of
histone H4 acetylation correlates with the preparation
of this locus to become transcriptionally active. Whether
histone H4 acetylation is necessary for transcription of
FMR1 remains to be determined.
Complementary patterns of histone H3 methylation
at lysines 4 and 9 are emerging as a common theme in
the difference between transcriptionally active and in-
active loci. For example, at the chicken b-globin locus,
transcriptionally active genes are associated with his-
tone H3 methylated at lysine 4, and transcriptionally
repressed genes are associated with methylation of his-
tone H3 at lysine 9 (Litt et al. 2001). Similarly, there is
a complementary pattern of histone H3 methylation at
lysines 4 and 9 at the Prader-Willi imprinting centers in
humans (Xin et al. 2001). Here we show that there is
also a complementary pattern of histone H3 methyla-
tion at lysine 4 and 9, associated with FMR1 in normal
and fragile X cells, that correlates with gene expression.
In normal cells, histone H3 associated with FMR1 is
methylated at lysine 4 but not at lysine 9. In fragile X
cells, histone H3 associated with FMR1 is undermethyl-
ated at lysine 4 and hypermethylated at lysine 9.
Methylation of histone H3 at lysine 9 at expanded
FMR1 alleles suggests that a histone methyltransferase,
such as SUV39H1 (Rea et al. 2000), is being targeted
to the locus. The chromodomain of the heterochromatin
protein HP1 has been shown to have an affinity for
histone H3 tails methylated at lysine 9, suggesting a
model in which methylation of histone H3 at lysine 9
targets HP1 to a locus resulting in heterochromatin for-
mation and transcriptional repression (Bannister et al.
2001; Lachner et al. 2001). Indeed, methylation of his-
tone H3 at lysine 9, directed by Rb, targets HP1 to the
cyclin E promoter, correlating with the repression of its
transcription (Nielsen et al. 2001). This model may also
apply to FMR1 in fragile X syndrome. Maintenance of
methylation of histone H3 at lysine 9 after TSA treat-
ment would explain why FMR1 remains in a condensed
state, despite an increase of histone H4 acetylation to
normal levels, since a chromodomain-containing pro-
tein, such as HP1, could remain targeted to the gene.
We also show that, after removal of azadC, there is
a coordinated remethylation of FMR1 DNA, renewed
deacetylation of histones, and transcriptional silencing.
This result demonstrates that these changes are not sta-
ble without the continuous presence of azadC. It also
reinforces the observation that these changes are tightly
coupled to the methylation state of the DNA. We em-
phasize that, although suggestive, the data do not prove
that these chromatin changes are causally involved in
transcription.
Like the marks of histone H3 and H4 acetylation,
methylation of histone H3 at lysine 4 increased after
azadC treatment, indicating that this modification is
also coupled to DNA methylation of FMR1. In contrast
to these changes, methylation of H3 at lysine 9 was
transient, decreasing to ∼50% of the starting level but
recovering to the original level by day 16. FMR1 tran-
scripts continued to accumulate throughout the course
of azadC treatment, indicating that the chromatin
changes due to drug treatment may override the re-
pressive effects of methylation of histone H3 at lysine
9, possibly by inhibiting binding of proteins, such as
HP1. Since there is an increase in acetylation but no net
change in methylation of H3 lysine 9 after 16 d, the
increase in acetylation must be due to acetylation of
other accessible lysine 9s of different H3 tails that reside
in the same nucleosome, on neighboring nucleosomes,
or even on different chromosomes in the population of
cells.
The continued association of partially demethylated
FMR1 DNA with histone H3 methylated at lysine 9,
coupled with the observation that FMR1 DNA becomes
remethylated after withdrawal of azadC, suggests that
undermethylated FMR1 DNA associated with histone
H3 methylated at lysine 9 could be a target for DNA
methyltransferase. This is consistent with a recent model
in which methylation of histone H3 at lysine 9 is a
determinant of DNA methylation (Tamaru and Selker
2001). In our working model, histone H3 associated
with expanded, unmethylated CGG repeat tracts would
become a target for a histone methyltransferase such as
SUV39H1. The association of FMR1 DNA containing
expanded CGG tracts with histone H3 methylated at
lysine 9 would then result in the targeting of a DNA
methyltransferase to FMR1 by association with a chro-
modomain-containing protein. There is precedent in
model organisms for the association of a DNA meth-
yltransferase activity with a chromodomain. For ex-
ample, in Arabidopsis thaliana, DNA methylation and
histone methylation are linked by a set of chromometh-
ylase proteins, which contain both a chromodomain
and the catalytic domain of a DNA methyltransferase
(Lindroth et al. 2001). It also has been shown recently
that, in N. crassa, DNA methylation is dependent upon
histone H3 methylation at lysine 9 and that disruption
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of histone methylation leads to DNA demethylation
(Tamaru and Selker 2001). In our working model, after
establishment of DNA methylation, HDACs and other
components of the transcriptional repression machinery
would be targeted to FMR1 by association with methyl
DNA-binding proteins, such as MeCP2, which con-
denses the chromatin at the locus, repressing transcrip-
tion of the gene. HDAC inhibitors are able to partially
reverse this process by inhibiting H4 deacetylation at
the locus, but, because histone H3 is methylated at ly-
sine 9, acetylation of this key amino acid would be
blocked, preventing the transition from a transcription-
ally silent condensed chromatin state back to a tran-
scriptionally active open chromatin state. This model
suggests the possibility that disruption of histone H3
methylation at lysine 9 at FMR1 in fragile X cells could
also lead to DNA demethylation, resulting in chromatin
opening and transcriptional reactivation of the gene.
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